Bullfrog AI Holdings, Inc. Warrants

BullFrog AI Holdings, Inc. is a digital biopharmaceutical company that uses artificial intelligence and machine learning (AI/ML) to analyze data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for analyzing preclinical and clinical data. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in treating human diseases including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, and with Johns Hopkins University for a formulation of Mebendazole for treating human cancer or neoplastic disease. Founded in 2017, it is based in Gaithersburg, Maryland.